Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Tecentriq Gets The Double At The EU CHMP

Executive Summary

Roche's checkpoint inhibitor Tecentriq clears the EU approval hurdle in locally advanced or metastatic urothelial carcinoma and locally advanced or metastatic non-small cell lung cancer.

You may also be interested in...



The Year's Clinical Trials In Review: Big Misses In 2017

The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.

Merck KGaA/Pfizer's Bavencio Set To Enter Europe's Crowded I-O Market

The highly-competitive PD-1 field in Europe is very likely to have a new player as Bavencio gets a CHMP recommendation for Merkel cell carcinoma, but the success of Merck KGaA and Pfizer's checkpoint inhibitor will be gauged on how it competes with the competition already on the market in wider, more valuable indications.

Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial

A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel